LAUSR

1. Clinical Study Protocol‐Amendment 2 AZD1222‐D8110C00001. A Phase III Randomized, Double‐blind, Placebo‐controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non‐replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID‐19. AstraZeneca; 2020. Available from: https:// astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=26198. [Last accessed on 2021 Jul 03]. 2. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. New Jersey: Wiley‐Interscience; 2003. 3. Burns J. If Nothing Goes Wrong, is Everything All Right? Why We Should Be Wary Of Zero Numerators. Vol. 16. Pediatric Critical Care Medicine. Lippincott Williams and Wilkins; 2015. p. 198‐9. 4. Hafiz I, Illian DN, Meila O, Utomo AR, Susilowati A, Susetya IE, et al. Effectiveness and efficacy of vaccine on mutated SARS‐CoV‐2 virus and post vaccination surveillance: A narrative review. Vaccines 2022;10:82. 5. Kim JH, Hotez P, Batista C, Ergonul O, Figueroa JP, Gilbert S, et al. Operation Warp Speed: Implications For Global Vaccine Security. Vol. 9, The Lancet Global Health. Elsevier Ltd; 2021. p. e1017‐21. Available from: https://pubmed.ncbi.nlm.nih.gov/33780663/. [Last accessed on 2021 Jul 03]. How to cite this article: Grech V, Grech E, Cuschieri S. Vaccine trials with no serious adverse reactions – estimation of upper 95% confidence intervals for likelihood of such events. Saudi J Anaesth 2022;16:506‐7.